

Are there other appropriate security measures that should be established to address the potential threats arising from the use of nucleic acid synthesis, given new and emerging technologies in the life sciences?

Are there new biosecurity risks posed by the introduction of new generations of benchtop DNA synthesizers capable of synthesizing and assembling dsDNA, RNA, single-stranded DNA, or oligonucleotides in-house that should be addressed by the Guidance?

As synthetic biology becomes an increasingly digital enterprise with large databases, digital tools, robotics, and artificial intelligence, what new risks are presented to providers and consumers of synthetic oligonucleotides?

If new risks are evident, how should these risks be addressed, keeping in mind the potential impacts on providers, customers, and scientific progress?

#### *Additional Considerations*

*The U.S. Government is committed to mitigating the potential biosecurity risks associated with synthetic DNA and its applications, while minimizing undue impacts on providers, customers, and scientific progress.*

Are there other mechanisms that the U.S. Government should consider for screening sequences, customers, or end-uses that may help mitigate the biosecurity risks associated with synthetic nucleotides and their applications, while minimizing undue impacts on providers, customers, and scientific progress?

(Authority: Section 301 of the Public Health Service Act, 42 U.S.C. 241; Section 605 of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, Pub. L. 116–22.)

**Robert P. Kadlec,**

*Assistant Secretary for Preparedness and Response.*

[FR Doc. 2020–18444 Filed 8–25–20; 8:45 am]

**BILLING CODE 4150–37–P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute on Alcohol Abuse And Alcoholism; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Initial Review Group; Epidemiology, Prevention and Behavior Research Review Subcommittee.

*Date:* October 19–20, 2020.

*Time:* 8:30 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Anna Ghambaryan, M.D., Ph.D., Scientific Review Officer, Extramural Project Review Branch, Office of Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Room 2120, MSC 6902, Bethesda, MD 20892, 301–443–4032, [anna.ghambaryan@nih.gov](mailto:anna.ghambaryan@nih.gov).

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; NIAAA and NIDA Institutional Research Training Grant (T32/T35) Review Panel.

*Date:* November 18, 2020.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Health, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Luis Espinoza, Ph.D., Scientific Review Officer, Extramural Project Review Branch, Office of Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, 6700B Rockledge Drive, Room 2109, Bethesda, MD 20892, (301) 443–8599, [espinozala@mail.nih.gov](mailto:espinozala@mail.nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: August 20, 2020.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020–18753 Filed 8–25–20; 8:45 am]

**BILLING CODE 4140–01–P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Special Emphasis Panel; BRAIN Initiative—Research Opportunities in Using Invasive and Stimulating Technologies in the Human Brain (ROH) U01 Review.

*Date:* September 29, 2020.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, NSC Building, 6001 Executive Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Tatiana Pasternak, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH NSC, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892, (301) 496–9223, [tatiana.pasternak@nih.gov](mailto:tatiana.pasternak@nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: August 20, 2020.

**Tyeshia M. Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2020–18761 Filed 8–25–20; 8:45 am]

**BILLING CODE 4140–01–P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Office of the Director, National Institutes of Health; Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Advisory Committee to